Sh
Shire (Takeda)
Dublin IEFounded 198624,000 employees
Private CappharmaAcquiredRare DiseaseHematology
Platform: Rare Disease
Market Cap
N/A
All Drugs
4
Clinical Trials
7
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| SHI-1915 | SHI-1915 | Phase 2 | 1 | CGRP | Myelofibrosis | ||
| SHI-2989 | SHI-2989 | Phase 2 | 2 | AHR | ADPKDGA | ||
| Peminaritide | SHI-3698 | Phase 1/2 | 2 | Aβ | Cervical Ca | ||
| SHI-2889 | SHI-2889 | Phase 2 | 2 | CFTR | CKDFabry |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (7)